系统性前列腺穿刺活检需要多少针?:一项大样本回顾性分析
该研究回顾性分析1211例经直肠超声引导12针系统性前列腺穿刺患者的临床数据,并推算6、8、10针方案的检出率。结果显示10针或12针方案检出率高于其他方案,但在前列腺特异性抗原浓度≥20 ng/mL的患者中,6针系统性穿刺活检更受推荐。
要点
- 10针与12针方案对前列腺癌和临床显著前列腺癌的检出率无显著差异(P > .05)。
- 前列腺最大横截面积小于15 cm²时,12针方案对临床显著前列腺癌的检出率优于其他方案(除10针外,P = .02-.04)。
- 前列腺特异性抗原浓度≥20 ng/mL的患者中,6针系统性穿刺活检更受推荐。
核心结论
- 10针或12针穿刺方案的检出率高于其他方案;但对于前列腺特异性抗原浓度≥20 ng/mL的患者,6针系统性穿刺活检更受推荐。
研究设计与样本
- 回顾性分析,纳入2011年1月至2018年3月接受经直肠超声引导12针系统性前列腺穿刺的1211例患者,并据此推算6、8、10针方案的检出情况。
诊断标准与关键数值
- 共检出前列腺癌498例(41.1%),临床显著前列腺癌423例(34.9%)。
- 12针与10针方案的前列腺癌和临床显著前列腺癌总检出率无显著差异(P > .05)。
- 前列腺最大横截面积小于15 cm²亚组中,12针与标准6针方案的前列腺癌检出率有显著差异(P = .03)。
- 前列腺最大横截面积小于15 cm²亚组中,12针方案对临床显著前列腺癌的检出率与其他方案(除10针外)有显著差异(P = .02-.04)。
- 前列腺特异性抗原浓度≥20 ng/mL的患者中,12针方案与其他所有方案均无显著差异(P > 0.05)。
临床应用与阅片要点
- 对于前列腺特异性抗原浓度≥20 ng/mL的患者,6针系统性穿刺活检更受推荐;其他情况下10针或12针方案检出率更高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To explore the best individualized systematic prostate biopsy method.
METHODS: We retrospectively analyzed the clinical data of 1211 patients who underwent 12-core systematic prostate biopsy guided by transrectal ultrasound from January 2011 to March 2018. Other biopsy core methods (6-, 8-, and 10-core) were estimated from the 12-core biopsy that was performed. Differences in the detection rates of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) were compared.
RESULTS: A total of 498 cases of PCa (41.1%) were detected, and 423 cases (34.9%) were csPCa. There was no significant difference between the 12- and 10-core prostate biopsy strategies in the total detection rates of PCa and csPCa (P > .05). In the subgroup of patients with a maximal prostate cross-sectional area of less than 15 cm2 , there was a significant difference between the 12-core method and the standard 6-core method (P = .03) but no significant differences between the other methods in the detection rate of PCa (P > .05), but in the detection rate of csPCa, the 12-core method differed significantly from the other methods (P = .02-.04) except for the 10-core method (P > .05). In patients with a prostate-specific antigen concentration of 20 ng/mL or higher, there were no significant differences between the 12-core method and all of the other methods (P > 0.05). In patients younger than 70 years and 70 years or older, the 12-core method differed significantly from the other methods (P < .01-.03) except for the 10-core method (P > .05).
CONCLUSIONS: Ten- or 12-core biopsy showed a higher detection rate than the other schemes. However, for patients with a prostate-specific antigen concentration of 20 ng/mL or higher, the 6-core systematic biopsy is preferred.
引用
- Hu Z, Wang J, Sun D, et al. How Many Cores Does Systematic Prostate Biopsy Need?: A Large-Sample Retrospective Analysis. J Ultrasound Med. 2018. PMID: 30380169. doi:10.1002/jum.14834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。